[EN] QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE<br/>[FR] COMPOSÉS DE QUINOLÉINE POUR AUGMENTER LA LIBÉRATION D'INSULINE
申请人:MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V
公开号:WO2017198756A1
公开(公告)日:2017-11-23
The present invention relates to a class of quinoline compounds that act as insulin secretagogues, i.e., induce insulin secretion from beta cells. The present compounds may be used to induce divalent calcium cation influx in pancreatic beta-cells or to activate voltage-dependent calcium channels in pancreatic beta-cells. The present invention further relates to compounds for use in the treatment of diabetes.
QUINOLINE COMPOUNDS FOR INCREASING INSULINE RELEASE
申请人:Max-Planck-Gesellschaft zur Förderung der
Wissenschaften e.V.
公开号:EP3246028A1
公开(公告)日:2017-11-22
The present invention relates to a class of quinoline compounds that act as insulin secretagogues, i.e., induce insulin secretion from beta cells. The present compounds may be used to induce divalent calcium cation influx in pancreatic beta-cells or to activate voltage-dependent calcium channels in pancreatic beta-cells. The present invention further relates to compounds for use in the treatment of diabetes.
Discovery of AL-GDa62 as a Potential Synthetic Lethal Lead for the Treatment of Gastric Cancer
作者:Andreas Luxenburger、Nicola Bougen-Zhukov、Michael G. Fraser、Henry Beetham、Lawrence D. Harris、Dorian Schmidt、Scott A. Cameron、Parry J. Guilford、Gary B. Evans
DOI:10.1021/acs.jmedchem.1c01609
日期:2021.12.23
optimize 1. Overall, 63 analogues were synthesized and tested for their SL activity toward isogenic mammary epithelial CDH1-deficient cells (MCF10A-CDH1–/–). Among the 26 compounds with greater cytotoxicity, AL-GDa62 (3) was four-times more potent and more selective than 1 with an EC50 ratio of 1.6. Furthermore, 3 preferentially induced apoptosis in CDH1–/– cells, and Cdh1–/– mammary and gastric organoids